Intellia Therapeutics(US:NTLA) Globenewswire·2026-03-03 12:30Core Insights - Intellia Therapeutics presented data on its investigational gene therapy, lonvo-z, at the 2026 AAAAI Annual Meeting, highlighting its potential to revolutionize treatment for hereditary angioedema (HAE) [1][6]. Group 1: Clinical Data and Findings - A pooled Phase 1/2 analysis involving 32 patients showed that a one-time 50 mg dose of lonvo-z resulted in a 96% reduction in HAE attacks, with a mean monthly attack rate consistently ≤0.2 over three years of follow-up [4]. - Among 28 patients with over six months of follow-up, 86% were attack-free and long-term prophylaxis-free, indicating significant treatment efficacy [4]. - Survey data revealed that 34% of surveyed patients experienced at least one attack per month, while only 20% reported being attack-free in the previous year, underscoring the ongoing treatment burden [3]. Group 2: Treatment Goals and Patient Needs - The primary treatment goals for HAE experts and patients include achieving attack-free status and minimizing treatment burden, as indicated by recent research [4]. - Most respondents in a survey indicated that eliminating lifetime chronic medication use and enhancing efficacy are crucial for improving their current therapy [5]. Group 3: Lonvo-z Overview and Regulatory Designations - Lonvo-z is based on CRISPR/Cas9 technology and aims to be the first one-time treatment for HAE by inactivating the KLKB1 gene, which encodes for prekallikrein [6]. - The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the FDA, Innovation Passport from the MHRA, and PRIME Designation from the EMA [6]. Group 4: Company Background - Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on leveraging CRISPR gene editing to develop potentially curative treatments for severe diseases [7]. - The company's mission is to transform the lives of patients by durably treating the root causes of diseases [7].